Tumor Biology

, Volume 37, Issue 7, pp 8715–8720 | Cite as

Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma

  • Yang-Jing Chen
  • Rui-Min Zhao
  • Qian Zhao
  • Bai-Ya Li
  • Qing-Yong Ma
  • Xiao Li
  • Xia Chen
Original Article


This study examined the association between hector battifora mesothelial antigen-1 (HBME-1) expression and papillary thyroid carcinoma (PTC). A total of 206 patients were enrolled in the current study including 96 PTC patients and 110 patients with benign thyroid nodules (BTN). Immunohistochemistry (Envision) were performed to assess the expression of HBME-1. Receiver operating characteristic curve (ROC) curves were applied to evaluate the diagnostic tumor node metastasis (TNM) value of HBME-1. Specimens from 96 patients with PTC and 110 patients with BTC were reviewed. HBME-1 was positively immunostained in PTC tissue, which was significantly higher than that in BTN tissues (77.1 vs. 5.77 %, P < 0.05). Immunohistochemistry also identified that HBME-1 expression did not show any statistically significant differences based on gender, age, tumor size, TNM stage, and lymph node metastasis (P > 0.05). Importantly, HBME-1 expression was correlated with infiltration levels and differential levels in PTC (both P < 0.05). HBME-1 was found to have high sensitivity (94.5 %) and specificity (77.08 %) for PTC diagnosis. Moreover, HBME-1 had a high specificity (83.33 %) at identifying the differential levels of PTC, but a low sensitivity (22.92 %). The sensitivity and specificity of HBME-1 identifying the infiltration levels of PTC were, respectively, 72.70 and 72.00 %. HBME-1 was highly expressed in PTC tissues, and HBME-1 can serve as a potential biomarker in the diagnosis of PTC.


HBME-1 Papillary thyroid carcinoma Immunohistochemistry ROC curve Sensitivity Specificity 



We would like to acknowledge the reviewers for their helpful comments on this paper.

Compliance with ethical standards

Conflict of interest



  1. 1.
    Dinets A, Pernemalm M, Kjellin H, Sviatoha V, Sofiadis A, Juhlin CC, et al. Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesions. PLoS One. 2015;10(5):e0126472.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Grant CS. Papillary thyroid cancer: Strategies for optimal individualized surgical management. Clin Ther. 2014;36(7):1117–26.CrossRefPubMedGoogle Scholar
  3. 3.
    Takahashi M, Saenko VA, Rogounovitch TI, Kawaguchi T, Drozd VM, Takigawa-Imamura H, et al. The foxe1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl. Hum Mol Genet. 2010;19(12):2516–23.CrossRefPubMedGoogle Scholar
  4. 4.
    Kim SK, Park HJ, Hong IK, Chung JH, Eun YG. A missense polymorphism (rs11466653, met326thr) of toll-like receptor 10 (tlr10) is associated with tumor size of papillary thyroid carcinoma in the Korean population. Endocrine. 2013;43(1):161–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Boufraqech M, Fassassi C, Kebebew E. Tlr-10 polymorphism and papillary thyroid cancer: one more snp to consider? Endocrine. 2013;43(1):10–1.CrossRefPubMedGoogle Scholar
  6. 6.
    Dinets A, Hulchiy M, Sofiadis A, Ghaderi M, Hoog A, Larsson C, et al. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chernobyl papillary thyroid carcinoma. Eur J Endocrinol. 2012;166(6):1049–60.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Owonikoko TK, Hossain MS, Bhimani C, Chen Z, Kim S, Ramalingam SS, et al. Soluble fas ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer. 2013;119(8):1503–11.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Schmitt AC, Cohen C, Siddiqui MT. Paired box gene 8, hbme-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma: diagnostic utility. Cancer Cytopathology. 2010;118(4):196–202.CrossRefPubMedGoogle Scholar
  9. 9.
    Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Caleo A, et al. Braf (v600e) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma. Endocrine. 2013;44(1):165–71.CrossRefPubMedGoogle Scholar
  10. 10.
    de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima FM, Del Giglio A, da Silva Pinhal MA. Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: Systematic review and diagnostic meta-analysis. Diagn Pathol. 2012;7:97.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of hbme1, galectin-3, ck19, and cited1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol. 2006;126(5):700–8.CrossRefPubMedGoogle Scholar
  12. 12.
    de Matos PS, Ferreira AP, de Oliveira FF, Assumpcao LV, Metze K, Ward LS. Usefulness of hbme-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005;47(4):391–401.CrossRefPubMedGoogle Scholar
  13. 13.
    Nga ME, Lim GS, Soh CH, Kumarasinghe MP. Hbme-1 and ck19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol. 2008;36(8):550–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Cui W, Sang W, Zheng S, Ma Y, Liu X, Zhang W. Usefulness of cytokeratin-19, galectin-3, and hector battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules. Clin Lab. 2012;58(7-8):673–80.PubMedGoogle Scholar
  15. 15.
    Fadda G, Rossi ED, Raffaelli M, Pontecorvi A, Sioletic S, Morassi F, et al. Follicular thyroid neoplasms can be classified as low- and high-risk according to hbme-1 and galectin-3 expression on liquid-based fine-needle cytology. Eur J Endocrinol. 2011;165(3):447–53.CrossRefPubMedGoogle Scholar
  16. 16.
    Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14(4):338–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y, et al. Hbme-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J. 2003;50(2):173–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Chung SY, Park ES, Park SY, Song JY, Ryu HS. Cxc motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma. Head Neck. 2014;36(7):1005–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Beesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002;41(3):236–43.CrossRefPubMedGoogle Scholar
  20. 20.
    Zintzaras E, Ioannidis JP. Hegesma: Genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg. 2007;31(5):916–23.CrossRefPubMedGoogle Scholar
  22. 22.
    Faquin WC, Baloch ZW. Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to national cancer institute (nci) recommendations. Diagn Cytopathol. 2010;38(10):731–9.PubMedGoogle Scholar
  23. 23.
    Ohori NP, Wolfe J, Hodak SP, LeBeau SO, Yip L, Carty SE, et al. "Colloid-rich" follicular neoplasm/suspicious for follicular neoplasm thyroid fine-needle aspiration specimens: cytologic, histologic, and molecular basis for considering an alternate view. Cancer Cytopathology. 2013;121(12):718–28.CrossRefPubMedGoogle Scholar
  24. 24.
    Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of hbme1 combined with ck19 immunostaining. Mod Pathol. 2006;19(12):1631–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Lansoy-Kuhn C, Picquenot JM, Edet-Sanson A, Mechken F, Laberge-Le Couteulx S, Cornic M, et al. Relationship between the immunohistochemistry of the primary tumour and 18f-fdg-pet/ct at recurrence in patients with well-differentiated thyroid carcinoma. Nucl Med Commun. 2013;34(4):340–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: Galectin-3, hbme-1, and cytokeratin-19. Endocr Pathol. 2010;21(2):80–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D, Savin S. Combined immunohistochemistry for thyroid peroxidase, galectin-3, ck19 and hbme-1 in differential diagnosis of thyroid tumors. APMIS. 2012;120(5):368–79.CrossRefPubMedGoogle Scholar
  28. 28.
    Wu G, Wang J, Zhou Z, Li T, Tang F. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: Improvement in the sensitivity or specificity? J Int Med Res. 2013;41(4):975–83.CrossRefPubMedGoogle Scholar
  29. 29.
    Saleh HA, Jin B, Barnwell J, Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol. 2010;5:9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X, et al. Diagnostic significance of ck19, ret, galectin-3 and hbme-1 expression for papillary thyroid carcinoma. J Clin Pathol. 2010;63(9):786–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Nechifor-Boila A, Borda A, Sassolas G, Hafdi-Nejjari Z, Borson-Chazot F, Lifante JC, et al. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using hbme-1 and cd56. Pathol Res Pract. 2013;209(9):585–92.CrossRefPubMedGoogle Scholar
  32. 32.
    Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and hbme-1. Endocr Pathol. 2003;14(1):55–60.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Yang-Jing Chen
    • 1
  • Rui-Min Zhao
    • 1
  • Qian Zhao
    • 1
  • Bai-Ya Li
    • 1
  • Qing-Yong Ma
    • 2
  • Xiao Li
    • 1
  • Xia Chen
    • 1
  1. 1.Department of Ent Head and Neck SurgeryFirst Affiliated Hospital of Xi’an Jiaotong UniversityXi’anPeople’s Republic of China
  2. 2.Department of Liver and Gallbladder SurgeryFirst Affiliated Hospital of Xi’an Jiaotong UniversityXi’anPeople’s Republic of China

Personalised recommendations